Pfizer announces approval by the China Food And Drug Administration Of XELJANZ, the first oral JAK inhibitor for adult patients with moderately to severely active rheumatoid arthritis

17th March 2017 Uncategorised 0

Pfizer

More: Pfizer announces approval by the China Food And Drug Administration Of XELJANZ, the first oral JAK inhibitor for adult patients with moderately to severely active rheumatoid arthritis
Source: MDlinx